ARCH ready for big bets with new $400m venture fund

ARCH Venture Partners raised $400m for its eighth venture capital fund of which 50% to 75% is likely to be invested in biotechnology, including contributions to one or two big ideas for groundbreaking therapeutic platforms or other compelling opportunities.

ARCH Venture Partners raised $400m for its eighth venture capital fund of which 50% to 75% is likely to be invested in biotechnology, including contributions to one or two big ideas for groundbreaking therapeutic platforms or other compelling opportunities.

Seattle, Washington-based ARCH, which has raised more than $1.9bn in its 28 years, has shown that it's not afraid of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category